BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37024611)

  • 1. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA; ElMeshad AN; Fares AR
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
    Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
    Rangaraj N; Pailla SR; Chowta P; Sampathi S
    AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic understanding of salt-induced drug encapsulation in nanosuspension via acid-base neutralization as a nanonization platform technology to enhance dissolution rate of pH-dependent poorly water-soluble drugs.
    Van Ngo H; Park C; Tran TTD; Nguyen VH; Lee BJ
    Eur J Pharm Biopharm; 2020 Sep; 154():8-17. PubMed ID: 32634569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
    Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
    Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
    Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
    Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
    Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
    Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
    Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM; Hamza MY; Abdelbary AA
    AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ; Gajera BY; Dave RH
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
    Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
    Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
    Pınar SG; Canpınar H; Tan Ç; Çelebi N
    Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
    Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.